GSK PLC Sponsored ADR $GSK Shares Acquired by Prime Capital Investment Advisors LLC

Key Points

• Prime Capital Investment Advisors LLC increased its stake in GSK by 182.7%, buying an additional 19,509 shares to hold 30,188 shares worth about $1.48 million at the end of the quarter.
• GSK raised its quarterly dividend to $0.4856 (annualized $1.94), representing a 3.3% yield and a dividend payout ratio of 50.81%.
• Analyst sentiment is cautious: the consensus rating is "Reduce" (1 Buy, 7 Hold, 3 Sell) with an average target price of $44.13, while the stock recently traded near $58.23.

Prime Capital Investment Advisors LLC lifted its position in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 182.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,188 shares of the pharmaceutical company's stock after purchasing an additional 19,509 shares during the quarter. Prime Capital Investment Advisors LLC's holdings in GSK were worth $1,480,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in GSK. CNB Bank acquired a new stake in shares of GSK in the 3rd quarter valued at about $31,000. Triumph Capital Management acquired a new stake in shares of GSK in the 3rd quarter valued at about $40,000. Salomon & Ludwin LLC boosted its position in shares of GSK by 444.0% in the 3rd quarter. Salomon & Ludwin LLC now owns 952 shares of the pharmaceutical company's stock valued at $41,000 after purchasing an additional 777 shares during the period. Westside Investment Management Inc. boosted its position in shares of GSK by 98.6% in the 3rd quarter. Westside Investment Management Inc. now owns 991 shares of the pharmaceutical company's stock valued at $45,000 after purchasing an additional 492 shares during the period. Finally, 1248 Management LLC boosted its position in shares of GSK by 314.6% in the 3rd quarter. 1248 Management LLC now owns 1,053 shares of the pharmaceutical company's stock valued at $46,000 after purchasing an additional 799 shares during the period. 15.74% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Wall Street Zen cut GSK from a "strong-buy" rating to a "buy" rating in a research report on Saturday, March 7th. Weiss Ratings downgraded GSK from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Thursday, March 19th. TD Cowen reaffirmed a "hold" rating on shares of GSK in a research note on Monday, February 9th. Barclays reaffirmed an "underweight" rating on shares of GSK in a research note on Friday, February 20th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of GSK in a research note on Friday, January 16th. One research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat, GSK presently has an average rating of "Reduce" and a consensus target price of $44.13.

GSK Stock Performance

Shares of GSK stock opened at $58.23 on Friday. The company has a market cap of $118.28 billion, a price-to-earnings ratio of 15.74, a price-to-earnings-growth ratio of 3.39 and a beta of 0.46. The stock has a 50 day simple moving average of $56.48 and a 200-day simple moving average of $50.37. GSK PLC Sponsored ADR has a 12-month low of $33.53 and a 12-month high of $61.69. The company has a current ratio of 0.82, a quick ratio of 0.54 and a debt-to-equity ratio of 0.92.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, April 9th. Stockholders of record on Friday, February 20th were paid a dividend of $0.4856 per share. This is a positive change from GSK's previous quarterly dividend of $0.42. The ex-dividend date of this dividend was Friday, February 20th. This represents a $1.94 dividend on an annualized basis and a dividend yield of 3.3%. GSK's dividend payout ratio (DPR) is currently 50.81%.

Key GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: China approves Exdensur (depemokimab) for chronic rhinosinusitis with nasal polyps, widening commercial opportunity for an ultra long‑acting biologic and supporting GSK’s respiratory/biologics growth trajectory. GSK Balances Exdensur China Growth With US Portfolio Retrenchment
• Positive Sentiment: Analyst/coverage pieces (Zacks / Yahoo) highlight GSK as a momentum stock and attract longer‑term investor interest, which can support multiple expansion and buying interest from momentum/value investors. Why GSK (GSK) is a Top Momentum Stock for the Long-Term
• Neutral Sentiment: ViiV Healthcare (majority owned by GSK) launched a PSA campaign around National Youth HIV/AIDS Awareness Day — positive for brand and public health positioning but unlikely to move near‑term revenue materially. The Time to Talk about HIV is Now: ViiV Healthcare Launches "Still Here"
• Neutral Sentiment: Market commentary is mixed on valuation after a strong run; some investors are reassessing upside vs. risk given recent gains — this can increase volatility as positioning shifts. Is It Too Late To Reassess GSK LSE: GSK After Its Strong Share Price Run?
• Negative Sentiment: GSK withdrew its application for leucovorin calcium — a drug that recently received regulatory attention — removing a potential product avenue and creating regulatory/PR noise that could weigh on near‑term sentiment. GSK Nixes Application for Drug Touted by Trump for Autism
• Negative Sentiment: Short interest jumped ~29.7% to ~16.06M shares as of March 31, raising the short‑interest ratio to ~3.6 days of average volume — an increase in bearish positioning that can amplify downward moves and volatility. (No external link)

GSK Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK's core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.